TCM
NBIX icon

Tekla Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Tekla Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-110,400
Closed -$5.02M – 152
2016
Q2 		$5.02M Buy
+110,400
New +$5.08M 0.2% 87
2014
Q4 		– Sell
-281,600
Closed -$4.41M – 106
2014
Q3 		$4.41M Buy
+281,600
New +$4.21M 0.21% 84

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Tekla Capital Management's NBIX Position: Q2 2023 in Review

Tekla Capital Management held its Neurocrine Biosciences (NBIX) position steady in Q2 2023 at 112,908 shares worth $10.6M. The position accounts for 0.42% of the portfolio, ranked #55.

Tekla Capital Management first reported a position in NBIX in Q2 2013 and has held it in 41 quarters since. The position peaked at $34.9M in Q2 2016. 457 funds tracked by Wall St. Rank hold NBIX as of Q2 2023.

  • Tekla Capital Management held 112,908 shares of Neurocrine Biosciences worth $10.6M as of Q2 2023.
  • Tekla Capital Management left its Neurocrine Biosciences share count unchanged in Q2 2023.
  • Neurocrine Biosciences made up 0.42% of Tekla Capital Management's portfolio in Q2 2023, its #55 holding.
  • Tekla Capital Management first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 41 quarters since.
  • Tekla Capital Management's Neurocrine Biosciences position peaked at $34.9M in Q2 2016.
  • 457 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.